[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556073":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":34,"centralContacts":34,"locations":43,"responsibleParty":507,"collaborators":34,"id":509,"slug":510,"hasResults":511,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":34,"eligibilityCriteria":515,"healthyVolunteers":511,"sex":516,"minAge":517,"maxAge":34,"enrollmentInfo":518,"targetDuration":34,"studyType":521,"phases":522,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":90,"whyStopped":34,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":555},{"fullName":5,"class":6},"Telix Pharmaceuticals (Innovations) Pty Limited","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel","EXPERIMENTAL","Lutetium (177Lu) rosopatamab tetraxetan (177Lu-TLX591) 76 mCi (±10%) given approximately 14 days apart, plus SOC.\n\nSOC is either:\n\nConcurrent enzalutamide (starting dose 160 mg daily) + prednisone \u002F prednisolone (5 mg twice a day) or equivalent.\n\nor\n\nConcurrent abiraterone (starting dose 1,000 mg daily) + prednisone \u002F prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)\n\nor\n\nSequential Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg\u002Fm2 IV every 3 weeks given in combination with oral prednisone \u002F prednisolone (5mg twice a day) or equivalent for up to 10 cycles.",[13,14,15,16],"Drug: 177Lu-TLX591","Drug: Enzalutamide","Drug: Abiraterone","Drug: Docetaxel",{"label":18,"type":19,"description":20,"interventionNames":21},"Control Arm (Enzalutamide or Abiraterone or Docetaxel)","ACTIVE_COMPARATOR","SOC is either:\n\nEnzalutamide (starting dose 160 mg daily).\n\nor\n\nAbiraterone (starting dose 1,000 mg daily) + prednisone \u002F prednisolone (up to 10 mg once daily for the standard formulation)\n\nor\n\nDocetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg\u002Fm2 IV every 3 weeks given in combination with oral prednisone \u002F prednisolone 5mg twice a day (or equivalent) for up to 10 cycles",[14,15,16],[23,30,35,39],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","177Lu-TLX591","Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart",[9],[29],"Lutetium (177Lu) rosopatamab tetraxetan",{"type":24,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Enzalutamide","Enzalutamide (starting dose 160 mg daily)",[9,18],null,{"type":24,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Abiraterone","Abiraterone (starting dose 1,000 mg daily) + prednisone \u002F prednisolone (up to 10 mg per day for the standard formulation)",[9,18],{"type":24,"name":40,"description":41,"armGroupLabels":42,"otherNames":34},"Docetaxel","Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg\u002Fm2 IV every 3 weeks given in combination with oral prednisone \u002F prednisolone 5mg twice a day (or equivalent) for up to 10 cycles",[9,18],[44,58,68,78,88,107,117,127,137,145,166,178,194,211,227,244,260,274,290,306,322,338,353,368,387,403,423,439,454,473,491],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":34},"Chao Family Comprehensive Cancer Centre","ACTIVE_NOT_RECRUITING","Orange","California","92868","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-117.85311,33.78779,{"lat":56,"lon":55},{"facility":59,"status":46,"city":60,"state":61,"zip":62,"country":50,"countryCode":51,"cosmosGeoPoint":63,"geoPoint":67,"contacts":34},"Biogenix Molecular LLC","Miami","Florida","33165",{"type":53,"coordinates":64},[65,66],-80.19366,25.77427,{"lat":66,"lon":65},{"facility":69,"status":46,"city":70,"state":71,"zip":72,"country":50,"countryCode":51,"cosmosGeoPoint":73,"geoPoint":77,"contacts":34},"United Theranostics","Glen Burnie","Maryland","21061",{"type":53,"coordinates":74},[75,76],-76.62469,39.16261,{"lat":76,"lon":75},{"facility":79,"status":46,"city":80,"state":81,"zip":82,"country":50,"countryCode":51,"cosmosGeoPoint":83,"geoPoint":87,"contacts":34},"XCancer Omaha","Omaha","Nebraska","68130",{"type":53,"coordinates":84},[85,86],-95.94043,41.25626,{"lat":86,"lon":85},{"facility":89,"status":90,"city":91,"state":91,"zip":92,"country":50,"countryCode":51,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Columbia University Herbert Irving Comphrensive Cancer Center","RECRUITING","New York","10032",{"type":53,"coordinates":94},[95,96],-74.00597,40.71427,{"lat":96,"lon":95},[99,104],{"name":100,"role":101,"phone":102,"phoneExt":34,"email":103},"Lisa Sahadi","CONTACT","732-235-2466","mns2146@cumc.columbia.edu",{"name":105,"role":106,"phone":34,"phoneExt":34,"email":34},"Mark Stein","PRINCIPAL_INVESTIGATOR",{"facility":108,"status":46,"city":109,"state":110,"zip":111,"country":50,"countryCode":51,"cosmosGeoPoint":112,"geoPoint":116,"contacts":34},"University Hospital","Cleveland","Ohio","44106",{"type":53,"coordinates":113},[114,115],-81.69541,41.4995,{"lat":115,"lon":114},{"facility":118,"status":46,"city":119,"state":120,"zip":121,"country":50,"countryCode":51,"cosmosGeoPoint":122,"geoPoint":126,"contacts":34},"OHSU Knight Cancer Center","Portland","Oregon","97239",{"type":53,"coordinates":123},[124,125],-122.67621,45.52345,{"lat":125,"lon":124},{"facility":128,"status":46,"city":129,"state":130,"zip":131,"country":50,"countryCode":51,"cosmosGeoPoint":132,"geoPoint":136,"contacts":34},"Intermountain Health","Murray","Utah","84107",{"type":53,"coordinates":133},[134,135],-111.88799,40.66689,{"lat":135,"lon":134},{"facility":128,"status":46,"city":138,"state":130,"zip":139,"country":50,"countryCode":51,"cosmosGeoPoint":140,"geoPoint":144,"contacts":34},"Salt Lake City","84112",{"type":53,"coordinates":141},[142,143],-111.89105,40.76078,{"lat":143,"lon":142},{"facility":146,"status":90,"city":147,"state":148,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Westmead Hospital","Sydney","New South Wales","2143","Australia","AU",{"type":53,"coordinates":153},[154,155],151.20732,-33.86785,{"lat":155,"lon":154},[158,161,164],{"name":146,"role":101,"phone":159,"phoneExt":34,"email":160},"+61 2 8890 5200","wslhd-cpmcc-enquiries@health.nsw.gov.au",{"name":162,"role":101,"phone":163,"phoneExt":34,"email":34},"Study Coordinator","+61 2 8890 8383",{"name":165,"role":106,"phone":34,"phoneExt":34,"email":34},"Dr. Tania Moujaber",{"facility":167,"status":90,"city":147,"state":148,"zip":168,"country":150,"countryCode":151,"cosmosGeoPoint":169,"geoPoint":171,"contacts":172},"Nepean Hospital","2747",{"type":53,"coordinates":170},[154,155],{"lat":155,"lon":154},[173,176],{"name":162,"role":101,"phone":174,"phoneExt":34,"email":175},"+61 2 4734 2156","Nbmlhd-nm-research@health.nsw.gov.au",{"name":177,"role":106,"phone":34,"phoneExt":34,"email":34},"Dr. Veronica Wong",{"facility":179,"status":90,"city":180,"state":148,"zip":181,"country":150,"countryCode":151,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Wollongong Hospital","Wollongong","2500",{"type":53,"coordinates":183},[184,185],150.89345,-34.424,{"lat":185,"lon":184},[188,192],{"name":189,"role":101,"phone":190,"phoneExt":34,"email":191},"Carly Leighton","+61 2 4222 5200","ISLHD-CancerClinicalTrials@health.nsw.gov.au",{"name":193,"role":106,"phone":34,"phoneExt":34,"email":34},"Dr. Gary Tincknell",{"facility":195,"status":90,"city":196,"state":197,"zip":198,"country":150,"countryCode":151,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Australian Prostate Centre","Melbourne","Victoria","3051",{"type":53,"coordinates":200},[201,202],144.96332,-37.814,{"lat":202,"lon":201},[205,209],{"name":206,"role":101,"phone":207,"phoneExt":34,"email":208},"Prof Tony Costello","+61 3 8373 7600","info@apcr.org.au",{"name":210,"role":106,"phone":34,"phoneExt":34,"email":34},"Prof. Tony Costello",{"facility":212,"status":90,"city":213,"state":214,"zip":215,"country":150,"countryCode":151,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"GenesisCare Murdoch","Perth","Western Australia","6150",{"type":53,"coordinates":217},[218,219],115.8614,-31.95224,{"lat":219,"lon":218},[222,225],{"name":162,"role":101,"phone":223,"phoneExt":34,"email":224},"+61 8 9366 1500","kate.waswo@genesiscare.com",{"name":226,"role":106,"phone":34,"phoneExt":34,"email":34},"Dr. Aviral Singh",{"facility":228,"status":229,"city":230,"state":34,"zip":231,"country":150,"countryCode":151,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"Mater Health Services Pty Ltd","NOT_YET_RECRUITING","Brisbane","4101",{"type":53,"coordinates":233},[234,235],153.02809,-27.46794,{"lat":235,"lon":234},[238,242],{"name":239,"role":101,"phone":240,"phoneExt":34,"email":241},"Alice Hillman","+61 731637978","alice.hillman@mater.org.au",{"name":243,"role":106,"phone":34,"phoneExt":34,"email":34},"Niara Oliveira",{"facility":245,"status":90,"city":246,"state":34,"zip":247,"country":150,"countryCode":151,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"GenesisCare Maitland","East Maitland","2323",{"type":53,"coordinates":249},[250,251],151.58333,-32.75,{"lat":251,"lon":250},[254,258],{"name":255,"role":101,"phone":256,"phoneExt":34,"email":257},"Kristy Atherton","+61 249184519","kristy.atherton@genesiscare.com",{"name":259,"role":106,"phone":34,"phoneExt":34,"email":34},"Sangeetha Ramanujan",{"facility":261,"status":90,"city":262,"state":34,"zip":263,"country":150,"countryCode":151,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"Austin Health","Heidelberg","3084",{"type":53,"coordinates":265},[266,267],145.06667,-37.75,{"lat":267,"lon":266},[270],{"name":271,"role":101,"phone":272,"phoneExt":34,"email":273},"Tina Chen","+61 3 9496 5748","tina.chen@austin.org.au",{"facility":275,"status":90,"city":276,"state":34,"zip":277,"country":150,"countryCode":151,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"GensisCare Cabrini","Malvern","3144",{"type":53,"coordinates":279},[280,281],145.02811,-37.86259,{"lat":281,"lon":280},[284,288],{"name":285,"role":101,"phone":286,"phoneExt":34,"email":287},"Michelle Starmans","+61 448011828","michelle.starmans@genesiscare.com",{"name":289,"role":106,"phone":34,"phoneExt":34,"email":34},"Mario Guerrieri",{"facility":291,"status":90,"city":292,"state":34,"zip":293,"country":150,"countryCode":151,"cosmosGeoPoint":294,"geoPoint":298,"contacts":299},"GenesisCare North Adelaide","North Adelaide","5006",{"type":53,"coordinates":295},[296,297],138.59141,-34.90733,{"lat":297,"lon":296},[300,304],{"name":301,"role":101,"phone":302,"phoneExt":34,"email":303},"Geetanjali Rangnekar","+61 882158010","geetanjali.rangnekar@genesiscare.com",{"name":305,"role":106,"phone":34,"phoneExt":34,"email":34},"Tony Michele",{"facility":307,"status":90,"city":308,"state":34,"zip":309,"country":150,"countryCode":151,"cosmosGeoPoint":310,"geoPoint":314,"contacts":315},"Royal North Shore Hospital","Saint Leonards","2065",{"type":53,"coordinates":311},[312,313],144.71803,-38.17051,{"lat":313,"lon":312},[316,320],{"name":317,"role":101,"phone":318,"phoneExt":34,"email":319},"Sally McCowatt","+61 294631181","Sally.McCowatt@health.nsw.gov.au",{"name":321,"role":106,"phone":34,"phoneExt":34,"email":34},"Alexander Guminski",{"facility":323,"status":90,"city":324,"state":34,"zip":325,"country":150,"countryCode":151,"cosmosGeoPoint":326,"geoPoint":330,"contacts":331},"GenesisCare Tugun","Tugun","4224",{"type":53,"coordinates":327},[328,329],153.5,-28.15,{"lat":329,"lon":328},[332,336],{"name":333,"role":101,"phone":334,"phoneExt":34,"email":335},"Kristy Longhurst","+61 477 007 925","kristy.longhurst@genesiscare.com",{"name":337,"role":106,"phone":34,"phoneExt":34,"email":34},"Sagar Ramani",{"facility":339,"status":90,"city":340,"state":34,"zip":34,"country":341,"countryCode":342,"cosmosGeoPoint":343,"geoPoint":347,"contacts":348},"INITIO Medical Group","Burnaby","Canada","CA",{"type":53,"coordinates":344},[345,346],-122.95263,49.26636,{"lat":346,"lon":345},[349],{"name":350,"role":101,"phone":351,"phoneExt":34,"email":352},"Philip Cohen","604-678-9274","clinicaltrials@initiomedical.ca",{"facility":354,"status":90,"city":355,"state":34,"zip":34,"country":341,"countryCode":342,"cosmosGeoPoint":356,"geoPoint":360,"contacts":361},"Sunnybrook Research Institute","Toronto",{"type":53,"coordinates":357},[358,359],-79.39864,43.70643,{"lat":359,"lon":358},[362,367],{"name":363,"role":101,"phone":364,"phoneExt":365,"email":366},"Urban Emmenegger","(416) 480-6100","64928","urban.emmenegger@sunnybrook.ca",{"name":363,"role":106,"phone":34,"phoneExt":34,"email":34},{"facility":369,"status":90,"city":370,"state":371,"zip":372,"country":373,"countryCode":374,"cosmosGeoPoint":375,"geoPoint":379,"contacts":380},"Auckland City Hospital","Grafton","Auckland","92024","New Zealand","NZ",{"type":53,"coordinates":376},[377,378],174.76566,-36.86029,{"lat":378,"lon":377},[381,385],{"name":382,"role":101,"phone":383,"phoneExt":34,"email":384},"Sergei Bendrikovskii","+64 93074949","Ak-Researchassistant@TeWhatuOra.govt.nz",{"name":386,"role":106,"phone":34,"phoneExt":34,"email":34},"Simon Fu",{"facility":388,"status":90,"city":389,"state":34,"zip":390,"country":373,"countryCode":374,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"New Zealand Clinical Research - Christchurch","Christchurch","8011",{"type":53,"coordinates":392},[393,394],172.63333,-43.53333,{"lat":394,"lon":393},[397,401],{"name":398,"role":101,"phone":399,"phoneExt":34,"email":400},"Gill Savin","+6433729477","Prostact.christchurch@nzcr.co.nz",{"name":402,"role":106,"phone":34,"phoneExt":34,"email":34},"Anthony Rahman",{"facility":404,"status":229,"city":405,"state":34,"zip":34,"country":406,"countryCode":34,"cosmosGeoPoint":407,"geoPoint":411,"contacts":412},"Ankara Bilkent City Hospital","Ankara","Turkey (Türkiye)",{"type":53,"coordinates":408},[409,410],32.85427,39.91987,{"lat":410,"lon":409},[413,417,421],{"name":414,"role":101,"phone":415,"phoneExt":34,"email":416},"Can Abdan","+90 5309562789","can.abdan@rivercro.com",{"name":418,"role":101,"phone":419,"phoneExt":34,"email":420},"Samet Taştan","+90 554 242 0670","samet.tastan@rivercro.com",{"name":422,"role":106,"phone":34,"phoneExt":34,"email":34},"Elif Özdemir",{"facility":424,"status":90,"city":405,"state":34,"zip":34,"country":406,"countryCode":34,"cosmosGeoPoint":425,"geoPoint":427,"contacts":428},"Ankara University Cebeci Hospital",{"type":53,"coordinates":426},[409,410],{"lat":410,"lon":409},[429,433,437],{"name":430,"role":101,"phone":431,"phoneExt":34,"email":432},"Özlem Üstündağ","0 541 669 39 59","ozlem_ustundag@cellin.com.tr",{"name":434,"role":101,"phone":435,"phoneExt":34,"email":436},"Yüksel Ürün","+90 533 748 32 75","dr.yukselurun@gmail.com",{"name":438,"role":106,"phone":34,"phoneExt":34,"email":34},"Yuksel Urun",{"facility":440,"status":90,"city":405,"state":34,"zip":34,"country":406,"countryCode":34,"cosmosGeoPoint":441,"geoPoint":443,"contacts":444},"Hacettepe University Medical Faculty",{"type":53,"coordinates":442},[409,410],{"lat":410,"lon":409},[445,449,453],{"name":446,"role":101,"phone":447,"phoneExt":34,"email":448},"Eda Karabulut","+90 5359673678","eda.karabulut@medex-smo.com",{"name":450,"role":101,"phone":451,"phoneExt":34,"email":452},"Murat Bozkurt","(+90) 0532 492 4890","fanibozkurt@yahoo.com",{"name":450,"role":106,"phone":34,"phoneExt":34,"email":34},{"facility":455,"status":229,"city":456,"state":34,"zip":34,"country":406,"countryCode":34,"cosmosGeoPoint":457,"geoPoint":461,"contacts":462},"Maslak Acibadem Hospital","Istanbul",{"type":53,"coordinates":458},[459,460],28.94966,41.01384,{"lat":460,"lon":459},[463,467,471],{"name":464,"role":101,"phone":465,"phoneExt":34,"email":466},"Nur Ergin","90 (505) 558 70 45","beyzanur.ergin@medismart.com.tr",{"name":468,"role":101,"phone":469,"phoneExt":34,"email":470},"Doğukan Danışmant","+90 545 862 87 19","dogukan.danismant@medismart.com.tr",{"name":472,"role":106,"phone":34,"phoneExt":34,"email":34},"Tevfik F Cermik",{"facility":474,"status":90,"city":475,"state":34,"zip":34,"country":476,"countryCode":477,"cosmosGeoPoint":478,"geoPoint":482,"contacts":483},"University College London Hospitals","London","United Kingdom","UK",{"type":53,"coordinates":479},[480,481],-0.12574,51.50853,{"lat":481,"lon":480},[484,487,490],{"name":485,"role":101,"phone":34,"phoneExt":34,"email":486},"Ursula McGovern","ursula.mcgovern@nhs.net",{"name":488,"role":101,"phone":34,"phoneExt":34,"email":489},"Costi Alifrangis","constantine.alifrangis1@nhs.net",{"name":485,"role":106,"phone":34,"phoneExt":34,"email":34},{"facility":492,"status":90,"city":493,"state":34,"zip":34,"country":476,"countryCode":477,"cosmosGeoPoint":494,"geoPoint":498,"contacts":499},"Genesis Care Windsor","Windsor",{"type":53,"coordinates":495},[496,497],-0.6,51.48333,{"lat":497,"lon":496},[500,503,506],{"name":501,"role":101,"phone":34,"phoneExt":34,"email":502},"Nicola Dallas","Nicola.Dallas@genesiscare.co.uk",{"name":504,"role":101,"phone":34,"phoneExt":34,"email":505},"Philip Camilleri","Philip.camilleri@genesiscare.co.uk",{"name":501,"role":106,"phone":34,"phoneExt":34,"email":34},{"type":508,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100556073","phase-3-the-study-of-177lu-tlx591-plus-soc-versus-soc-alone-in-patients-with-mcrpc-prostact-global-100556073",false,"NCT06520345","The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment","Inclusion Criteria:\n\n* Be a male, at least 18 years old, with documented adenocarcinoma of the prostate defined by histological \u002F pathological confirmation.\n* Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of ≥6 months from Day 1.\n* Have metastatic disease (defined as ≥1 metastatic lesion present on baseline CT, MRI or bone scintigraphy).\n* Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing hormone \\[LHRH\\] analogues) and must have a castrate level of serum\u002Fplasma testosterone (\\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL) at Screening\n* Must have received a minimum of 12 weeks of prior therapy on an ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide), received in either the mCSPC, nmCRPC, or mCRPC treatment settings, with documented evidence of disease progression while receiving this ARPI. Progression must have occurred on the most recent ARPI. A prior ARPI may have been utilized, but no progression on the prior ARPI is allowed (e,g, ARPI was switched due to poor tolerability or due to adverse events). No washout period is required prior to enrollment into this trial. Participants may have received docetaxel in the mCSPC setting as per the CHAARTED or STAMPEDE treatment regimens (up to 6 cycles of docetaxel), provided the last dose of docetaxel was ≥ 6 months prior to screening and ≥ 4 cycles of docetaxel were administered.\n* Have a disease that is progressing at study entry, despite a castrate testosterone level (\\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL), by the demonstration of at least one of the following:\n* Two consecutive rising PSA values assessed sequentially at least one week apart, with the final measurement required to be a minimum of 2.0 ng\u002FmL for study entry. Only the last measurement must meet or exceed 2.0 ng\u002FmL.\n* Progressive disease or new lesion(s) in the viscera or lymph nodes as per RECIST1.1 or in bone as per PCWG3. Any ambiguous results are to be confirmed by other imaging modalities (e.g., CT or MRI scan).\n* Have disease that is PSMA-positive, as demonstrated by a 68Ga-PSMA-11 PET\u002FCT or PET\u002FMRI scan and confirmed as eligible by the Sponsor's appointed BICR.\n\nImaging-based eligibility review will be performed in two stages:\n\n1. Presence of metastases for exclusion: Screening CT and MRI will be assessed to exclude participants with brain metastasis with long-axis\\>1cm\n2. PSMA PET eligibility: Screening 68Ga-PSMA-11 PET\u002FCT or PET\u002FMRI will be assessed along with CT, MRI, and bone scans utilizing tumor to liver ratio (TLR) for PSMA positivity-based exclusion. TLR is defined as the ratio of tumor lesion SUVmax to liver SUVmean derived from a 3 cm 3D spherical region of interest (ROI).\n\nPSMA positivity is defined as : At least 1 lesion with PSMA TLR≥2.\n\nPSMA exclusion critieria: The presence of any of the following will result in the patient being ineligible for this trial:\n\ni) visceral metastatic lesions that are ≥1 cm that have a PSMA TLR\\\u003C 1 ii) Lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLF \\\u003C1.\n\niii) At least one metastatic lymph node lesion with short axis ≥2.5 cm with a TLF\\\u003C1.\n\n* Must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (i.e., surgery, local radiotherapy, ARPI, chemotherapy, etc.) with the exception of alopecia. Specific conditions may be discussed with the medical monitor as needed.\n* Have adequate organ function at Screening:\n\nBone marrow:\n\n* Platelets ≥150×109\u002FL.\n* Absolute neutrophil count ≥1.5 x 109\u002FL.\n* Hemoglobin \\>10g\u002FdL (with no red blood cell transfusion in the previous 4 weeks).\n\nLiver function:\n\n* Total bilirubin ≤ 1.5× the upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3× ULN is permitted.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3× ULN.\n\nRenal function:\n\n* Creatinine clearance ≥45 mL\u002Fmin determined using the Cockcroft-Gault formula.\n* Must understand the study and agree to adhere to all protocol requirements.\n* Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the public, especially if a female partner of the participant is or could be pregnant.\n* Must agree to practice adequate precautions to prevent pregnancy in a partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1 \\[Clinical Trial Coordination Group {CTCG, 2024}\\]).\n\nExclusion Criteria:\n\n* Is unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the Investigator.\n* Has PC associated with pathological findings consistent with small cell or any histology other than adenocarcinoma of the prostate. If there are minor (\\\u003C20%) elements of neuroendocrine histology, this is acceptable.\n* Participants with a history of other malignancies that could significantly impact life expectancy or interfere with disease assessment will be excluded. Exceptions apply to participants with:\n\n  1. Prior malignancy that has been adequately treated and has remained disease-free for at least 3 years (maybe confirmed by a scan, etc.).\n  2. Adequately treated non-melanoma skin cancer.\n  3. Superficial (non-muscle invasive) bladder cancer that is controlled and stable.\n* Has received prior treatment with monoclonal antibody (mAb) J591 or HuJ591 or any other PSMA targeted therapy.\n* Have received chemotherapy in the mCRPC or non-metastatic prostate cancer (nmCRPC) settings (note: prior docetaxel use in the mCSPC setting with CHAATERED or STAMPEDE regimens is permitted if the last dose of therapy was ≥6 months prior to screening and ≥4 cycles of docetaxel were administered).\n* Has known allergies, hypersensitivity, or intolerance to the investigational drug or its excipients.\n* Has received prior systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy, or biological therapy) and\u002For radiation therapy within 4 weeks of enrolment (excluding ARPI and\u002For LHRH analogues).\n\nOR are receiving other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy.\n\n* Has received prior treatment with radioisotopes, including but not limited to: 89Strontium, 153Samarium, 186Rhenium, 188Rhenium, 223Radium, or hemi-body irradiation within 6 months prior to enrolment.\n* Has received other investigational therapy within 4 weeks of enrolment.\n* Has known brain metastases with long-axis ≥1cm, or liver metastases with long-axis ≥1cm, or lytic bone metastases with long-axis ≥1cm.\n* Has a history of seizure and\u002For stroke within the past 6 months.\n* Has clinical or radiologic findings indicative of impending spinal cord compression or experience symptomatic spinal cord compression.\n* Has evidence of a serious active or sub-clinical infection or angina pectoris (New York Heart Association \\[NYHA\\] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment, particularly with enzalutamide.\n* Has received treatment with any PARP inhibitors (i.e., Olaparib) or with any platinum based anti-neoplastic drugs.","MALE","18 Years",{"count":519,"type":520},520,"ESTIMATED","INTERVENTIONAL",[523],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment",[526],"Metastatic Castration-resistant Prostate Cancer",[528,529,530,40,531,532,533,534,535,536,25,537,538,539,540,541,542,543,544,545],"Radiographic Progression Free Survival","Overall Survival","ARPI","Prostate Cancer","Radionuclide therapy","TLX591","ProstACT Global","PSMA- targeting agent","mCRPC","mCSPC","nmCRPC","rosopatamab tetraxetan","Lutetium","177-Lutetium","Objective Response Rate (ORR)","PSA","68Gallium-PSMA-PET","Radio-Labelled Antibody Drug Conjugate (rADC)","2026-06-16",{"date":548,"type":549},"2026-06-18","ACTUAL",{"date":551,"type":549},"2024-07-26",{"date":553,"type":520},"2030-12",{"name":5,"class":6},31]